Participated · Equity · May 2024

Watershed Health offers a real-time care coordination SaaS platform that becomes the single point of connection among a patient’s clinical and non-clinical providers to reduce costs and improve outcomes. The platform supplies a shared patient record with curated, real-time clinical data, social determinants of health, and contact information, and it integrates with existing EHRs and HIEs. Watershed is HITRUST-certified and supports HIPAA compliance, while generating proprietary quality measures and a virtual workspace for provider communication and care-plan execution. Current customers include four out of six major US health plans and thousands of providers delivering care to more than five million patients. Founded in 2013 to help the Alabama Gulf Coast region, the company has expanded geographically and plans to scale across the United States. The new capital will be used to meet payer and provider demand and to grow engineering, development, customer success and sales teams.

Participated · Series A · Dec 2022

Carallel delivers expert, human-led guidance combined with digital tools to identify and empower family caregivers and help them manage caregiving needs. The company partners with health plans, providers, and employers to improve outcomes and member experience. Carallel already supports more than 400,000 Medicare Advantage and commercially insured members and their caregivers nationally. According to a 2020 survey of users, Carallel reduced stress for 90% of caregivers and improved decision-making confidence for 87%, and the company reports a Net Promoter Score of 88. With new funding, Carallel plans to expand its reach in Medicare Advantage and commercial markets, build dynamic digital experiences, expand peer-to-peer support, and deploy targeted care interventions. The company says these efforts aim to improve quality metrics such as Medicare Star Ratings and CAHPS performance.

Participated · Convertible Note · Jun 2022

Trusty.care is a New York-based insurtech that provides an AI-driven 360 sales enablement solution for the individual health insurance and Medicare distribution market. Its products are used by insurance sales professionals to streamline quoting, enrollment, commissions, contracting, and licensing workflows. For carriers and FMOs the platform aims to improve retention, reduce spend on manual processes, and improve NPS. Trusty.care’s distribution model reaches consumers through partnerships, brokers, and carriers; contracted brokers grew from 1,000 to 50,000 in the last 18 months and the company works with 300+ health plan customers. The company plans to use new capital to grow the team, forge partnerships, ramp marketing, launch a Medicare Advantage retention product, and expand digital enrollment to 200+ health plans. The round brings Trusty.care’s total funding to $13M. Trusty.care operates a dual-facing digital platform that helps health insurance brokers and financial advisors identify financial risks older clients may face from healthcare costs. The platform matches customers with insurance products, public benefits, and cost-saving tools and includes both a consumer-facing marketplace and a broker-facing SaaS. The company sells its product on a per-broker SaaS basis and takes a share of transaction fees on the marketplace. Trusty.care's founders were inspired by hands-on eldercare experience and personal family healthcare events; CEO and cofounder Joseph Schneier discussed this background. The team is building data science behind a COVID-19 application that state governments are using to manage older adult residents, and they are using that data to inform their insurance business. The company has moved from pre-revenue to converting customers to paying and plans to reach 15,000 brokers and at least $100K MRR in the next six months. To date Trusty.care has raised $4.3M in total capital across multiple rounds. Trusty.care is a New York-based healthcare technology startup that provides a senior-focused, data-driven platform for Medicare beneficiaries. The platform uses predictive analytics to help reduce healthcare costs for seniors. It soft-launched on Oct. 15, 2018, providing data on 100 Medicare-covered medications. The platform has been authorized by CMS for integration with beneficiary claims data via Blue Button 2.0. The company raised $800k in pre-seed funding and intends to use the proceeds to expand operations and its business reach. Trusty.care is led by CEO Joseph Schneier.

Participated · Series A · Feb 2022

QbDVision offers a purpose-built Digital CMC (Chemistry, Manufacturing, and Controls) platform that structures, curates, and links CMC data across the product lifecycle to create a unified knowledge asset. The cloud-based platform is designed to replace siloed, document-centric workflows and to automate key development and tech-transfer processes, providing real-time guidance for data-driven decision making. Customers include three of the top six global pharma and biotech companies, and the product is positioned to improve regulatory readiness and reduce cycle times. The company emphasizes enabling AI-driven innovation by delivering trustworthy, highly contextualized CMC knowledge needed for predictive CMC models. QbDVision intends to expand commercial operations and accelerate adoption of Digital CMC as a strategic knowledge foundation for drug development and manufacturing. QbDVision offers a cloud-based digital CMC workspace designed to enhance the curation, utilization, and integrity of process development data. The platform creates a structured digital framework for integrating CMC workflows, embedding best practices for process design, and managing product and process knowledge. Developed by a team of drug development experts, the solution aims to accelerate therapies to patients by improving data and workflow management. The company serves a commercial market that already includes enterprise pharma, biotech, and CDMO customers across the world. Led by CEO Yash Sabharwal and based in Austin, TX, QbDVision plans to use recent funding to drive expansion of its commercial market. Financially, the company has raised a total of $20M to date. CherryCircle Software develops cloud-based software to manage the development of complex manufacturing processes in regulated industries, with a flagship product, QbDVision, focused on the pharmaceutical sector. QbDVision applies quality-by-design principles and is aligned with ISPE’s Pharma 4.0 initiatives. The company released an Americana version of QbDVision in September 2018 and reports immediate adoption. CherryCircle is ramping up sales and marketing activities to grow its customer base. The company plans to use proceeds from its seed financing to hire staff, expand its platform, and scale customer operations. CherryCircle was founded in 2016 by Yash Sabharwal and Ryan Shillington and is based in Austin, Texas.

Participated · Series B · Aug 2020

Exo develops a handheld ultrasound device together with Exo Works, a point-of-care workflow platform that streamlines exam review, documentation and billing in under one minute. The device combines artificial intelligence, medical imaging and silicon technology to enable use in settings from cardiology to lung scans and at-home monitoring. Exo says the device will cost around the price of a laptop, aiming to make ultrasound more widely accessible. The company is focused immediately on commercializing the device, building out its informatics platform (currently being piloted across the U.S.), and ramping production and its sales force. Exo has raised over $320 million in total funding since its 2015 founding, including a $40 million raise in 2020. The company plans to bring the handheld device to market after securing U.S. FDA approval and is based in Redwood City, California. Exo is developing a handheld ultrasound device built on patented Piezoelectric Micromachined Ultrasound Transducer (pMUT) technology intended to deliver industry-leading image quality, affordability and portability. The device is paired with cloud-based workflow software and data apps designed to improve interoperability, documentation and clinician workflow in emergency and critical care settings. Exo will use its Series B+ funding to finish product development and bring its data and workflow apps to market. The company says its technology is intended to image denser body compositions and provide powerful diagnostic capabilities for frontline physicians. Exo highlights a team with experience from Apple, GE, Google, Johnson & Johnson, Maxim, Medtronic and Siemens and envisions a multi-functional platform that could converge diagnostics and therapeutics. Financially, the Series B+ follows an August 2019 Series B that raised $35 million and brings Exo’s total funding to nearly $100 million.